Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*
Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, et al.
British Journal of Dermatology (2020) Vol. 184, Iss. 6, pp. 1094-1105
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 567-579
Open Access | Times Cited: 96
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
Tiago Torres, L. Puig, Ronald Vender, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 6, pp. 891-904
Closed Access | Times Cited: 52
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sarah E. Thomas, Liana Barenbrug, Gerjon Hannink, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 565-578
Open Access | Times Cited: 14
Impact of prior biologic exposure on drug survival in atopic dermatitis
Xu Li, Shuang Wu, Yanfei Li, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access | Times Cited: 1
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Andreas Pinter, L. Puig, Knut Schäkel, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2087-2100
Open Access | Times Cited: 27
Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
Adam Reich, Catherine Reed, Christopher Schuster, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 16
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
Thomas Graier, Wolfgang Weger, Constanze Jonak, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists
Álvaro González‐Cantero, M. Constantin, Annunziata Dattola, et al.
International Journal of Women’s Dermatology (2023) Vol. 9, Iss. 4, pp. e112-e112
Open Access | Times Cited: 13
Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study
Tetsuji Yanase, Noriko Tsuruta, Kazuki Yamaguchi, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 6, pp. 753-765
Closed Access | Times Cited: 11
Durability and long-term outcomes of biologic therapies in psoriasis
Lluís Rusiñol, Elena Carmona‐Rocha, L. Puig
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 1, pp. 71-82
Closed Access | Times Cited: 11
Drug survival of biologics in psoriasis: An Australian multicentre retrospective study
Samantha Ting, Patricia Lowe, Annika Smith, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 4, pp. 350-357
Open Access | Times Cited: 4
Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study
Andrea Chiricozzi, Giulia Coscarella, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 11, pp. 2175-2185
Closed Access | Times Cited: 4
Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review
E. Daudén, José María Ortiz Salvador, J. Notario, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 478-478
Open Access
Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics
Elizabeth Lazaridou, Zoé Apalla, Stylianos Ravanidis, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry
Liana Barenbrug, Renate G. van der Molen, Jake S.F. Maurits, et al.
Journal of Psoriasis and Psoriatic Arthritis (2025)
Closed Access
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
Charles Lynde, Elisabeth Riedl, Julia‐Tatjana Maul, et al.
Advances in Therapy (2022) Vol. 40, Iss. 3, pp. 869-886
Open Access | Times Cited: 16
Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study
Zheng Zhao, Zhanglei Mu, Yan Zhao, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113474-113474
Closed Access | Times Cited: 3
Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
Ying Li, Jiajing Lu, Xiaoyuan Zhong, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2245-2252
Open Access | Times Cited: 13
Blocking interleukin‐17 in psoriasis: Real‐world experience from the PsoPlus cohort
Lisa Schots, Rani Soenen, Brigitte Blanquart, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 698-710
Open Access | Times Cited: 13
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain
E. Daudén, Glauber Pacelli Gomes de Lima, Susana Armesto, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 6, pp. 2207-2215
Open Access | Times Cited: 18
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
Andrew Blauvelt, Russel Burge, Gaia Gallo, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 3, pp. 701-714
Open Access | Times Cited: 12
Real‐world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study (RAILWAY)
Yayoi Tada, Akimichi Morita, Keiichi Yamanaka, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 11, pp. 1415-1426
Open Access | Times Cited: 7
Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience
Fatma Elif Yıldırım, Fatma Aslı Hapa
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 1, pp. 49-55
Open Access | Times Cited: 2
Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
L. S. van der Schoot, J.M.P.A. van den Reek, Lynda Grine, et al.
Trials (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
Francesco Bellinato, Paolo Gisondi, Elena Jane Mason, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1303-1311
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top